Semaglutide · source year
6 selected, source-linked Semaglutide records carrying a 2023 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
2 represented types.
6 distinct public records.
Cited chronology
Regulatory
The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.